Market Overview

UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated

Share:

Posted-In: News FDA

 

Related Articles (PPHM)

Get Benzinga's Newsletters